1 / 16

UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005

EU Research and Patient Safety. UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005. Kevin McCarthy, European Commission Health Research Directorate, DG Research,. Patient Safety Research & Europe. Factors influencing such research in the European context:.

knut
Download Presentation

UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. EU Research andPatient Safety UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European CommissionHealth Research Directorate, DG Research,

  2. Patient SafetyResearch & Europe Factors influencing such research in the European context: Deliberations at the European level - HLG Research support to operational / policy services FP6 - Scientific Support to Policy emphasis on patient mobility and quality issues: SSP projects: E4P & MARQUIS … Experience from current and completed projects – Internal Market (4FP), REBEQI, QM in Health (5FP) Deliberations at the international & regional levels – World Alliance, WHO/EURO work The next FP …

  3. Patient SafetyResearch & Europe A pan-European approach : Europe is a natural laboratory Critical mass on best practice Health policy-driven research  allows comparisons of national models & data Experience at the international level

  4. The Patient & FP7(2007-2013) • Health • Food, agriculture and biotechnology • Information and communication technologies • Nanosciences, nanotechnologies, materials and new production technologies • Environment (including climate change) • Socio-economic sciences and the humanities

  5. Health Research Theme • Under each theme there will be sufficient flexibility to address both Emerging needs and Unforeseen policy needs • Dissemination of knowledge and transfer of results will be supported in all thematic areas • Support will be implemented across all themes through: Collaborative research (Collaborative projects; Networks of Excellence; Coordination/support actions) Joint Technology Initiatives Coordination of non-Community research programmes (ERA-NET; ERA-NET+; Article 169) International Cooperation

  6. HEALTH THEME - COLLABORATIVE RESEARCH Objective: Improving the health of European citizens Increasing the competitiveness of European health-related industries and businesses Addressing global health issues including emerging epidemics

  7. FP7 HEALTH RESEARCH Activities  3 Pillars Biotechnology, generic tools and technologies for human health Translating research for human health Optimising the delivery of health care to European citizens

  8. FP7 & PATIENT SAFETY Third Pillar: Optimising the delivery of health care to European citizens Enhanced health promotion and disease prevention Translating clinical research into clinical practice Quality, solidarity and sustainability of heath systems

  9. FP7 & PATIENT SAFETY I. Enhanced health promotion & disease prevention: Provide evidence for the best public health measures in terms of life styles and interventions - different levels & different contexts Focus on the wider determinants of health and how they interact at both the individual and community level: For example diet, stress, tobacco and other substances, physical activity, cultural context, socio-economic and environmental factors. Mental health to be addressed in a life-course perspective

  10. FP7 & PATIENT SAFETY II.Translating clinical research into clinical practice: Better use of medicines, and appropriate use of behavioural and organisational interventions and health therapies and technologies Special attention paid to patient safety: to identify the best clinical practice to understand decision making in clinical settings in primary and specialised care to foster applications of evidence-based medicine and patient empowerment Focus the benchmarking of strategies; investigating outcomes of different interventions including medicines, taking into consideration pharmacovigilance evidence, specificities of the patient (e.g. genetic susceptibility, age, gender and adherence) and cost benefits

  11. FP7 & PATIENT SAFETY III. Quality, Solidarity and sustainability of health systems: Basis for countries to adapt their health systems National contexts and population characteristics taken into account Organisational, financial and regulatory aspects Implementation Outcomes - effectiveness, efficiency and equity Special attention on investment issues and human resources

  12.  Innovative Medicines Joint Technology Initiative Long term objective: To increase the competitiveness of the European Pharmaceutical industry, and to foster Europe as the most attractive place for pharmaceutical R&D. Thereby enhancing access of innovative medicines to the benefit of patients and society. Aim: To remove major bottlenecks in the drug development process, as identified by industry, and where research is the key.

  13. Innovative Medicines Initiative • Industry (under the leadership of EFPIA) has identified the bottlenecks in agreement with key stakeholders: academia, regulatory agencies, patient organisations, clinical researchers, ethical experts, etc. • A Strategic Research Agenda prioritising the research needs and how they should be implemented has been developed by panels of experts: • Prediction of safety • Earlier indication of efficacy • Knowledge management • Education & training

  14. Potential areas:Patient Safety Research (i): • Domains identified by the HLG: • Financial costs and benefits of implementing improved systems – inter-relationships, economic analysis • Contribution to design for safety – SMEs are innovative • Networking – ERA-Net tool • New knowledge and better understanding e.g. magnitude and quality of adverse events outside the hospital setting • Engaging with the patient, with society – communication • Links to international and regional developments – World Alliance, WHO

  15. Potential areas:Patient Safety Research (ii): • Major scientific conference and public health intervention research – a 6th FP SSP initiative: 5th Call • FP7 - A health systems approach with appropriate methodologies being developed: • epidemiology of adverse events - identification, measurement, frequency, causes, determinants, and impact on patient outcomes • effective methods for preventing such events; • optimizing patient safety, best practice • Evidence-based medicine • Contributions from IT, nanotechnologies

  16. Information • EU research: http://europa.eu.int/comm/research • Seventh Framework Programme: http://europa.eu.int/comm/research/future/index_en.cfm • Information on research programmes and projects: http://www.cordis.lu • RTD info magazine: http://europa.eu.int/comm/research/rtdinfo/ • Information requests:research@cec.eu.int

More Related